Skip to content
Intelligence IAMay 15, 2026Intelligence IA
Article

TuHURA Biosciences, an immuno-oncology company, released Q1 2026 financial results.

The company is developing novel therapies to overcome resistance to cancer immunotherapy.

Redaction Data Cube AISource: PR Newswire
01

Brief source

TuHURA Biosciences, an immuno-oncology company, released Q1 2026 financial results. The company is developing novel therapies to overcome resistance to cancer immunotherapy.